FDA Approves First Treatment for Rare Eye Disease

The FDA approved Dompé’s Oxervate (cenegermin) as a first treatment for neurotrophic keratitis in patients older than two years.

The treatment offers complete healing of the cornea for many patients, avoiding surgical procedures like corneal transplants and alternatives such as antibiotics, artificial tears and autologous serum-derived eye drops.

The drug acts directly on corneal cells, stimulating their growth and survival and attaching to receptors on lacrimal glands to induce tear production.